Literature DB >> 22845482

How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Shuji Ogino1, Charles S Fuchs, Edward Giovannucci.   

Abstract

Cancers are complex multifactorial diseases. For centuries, conventional organ-based classification system (i.e., breast cancer, lung cancer, colon cancer, colorectal cancer, prostate cancer, lymphoma, leukemia, and so on) has been utilized. Recently, molecular diagnostics has become an essential component in clinical decision-making. However, tumor evolution and behavior cannot accurately be predicted, despite numerous research studies reporting promising tumor biomarkers. To advance molecular diagnostics, a better understanding of intratumor and intertumor heterogeneity is essential. Tumor cells interact with the extracellular matrix and host non-neoplastic cells in the tumor microenvironment, which is influenced by genomic variation, hormones, and dietary, lifestyle and environmental exposures, implicated by molecular pathological epidemiology. Essentially, each tumor possesses its own unique characteristics in terms of molecular make-up, tumor microenvironment and interactomes within and between neoplastic and host cells. Starting from the unique tumor concept and paradigm, we can better classify tumors by molecular methods, and move closer toward personalized cancer medicine and prevention.

Entities:  

Mesh:

Year:  2012        PMID: 22845482      PMCID: PMC3492839          DOI: 10.1586/erm.12.46

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  106 in total

Review 1.  A continuum model for tumour suppression.

Authors:  Alice H Berger; Alfred G Knudson; Pier Paolo Pandolfi
Journal:  Nature       Date:  2011-08-10       Impact factor: 49.962

2.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

3.  The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory.

Authors:  Ana M Soto; Carlos Sonnenschein
Journal:  Bioessays       Date:  2011-05       Impact factor: 4.345

4.  Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.

Authors:  Shuji Ogino; Takako Kawasaki; Gregory J Kirkner; Yuko Suemoto; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Gut       Date:  2007-03-05       Impact factor: 23.059

Review 5.  Human cancers express mutator phenotypes: origin, consequences and targeting.

Authors:  Lawrence A Loeb
Journal:  Nat Rev Cancer       Date:  2011-05-19       Impact factor: 60.716

6.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

7.  Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.

Authors:  Paul J Limburg; David Limsui; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-15       Impact factor: 4.254

8.  Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Authors:  Xiaoyun Liao; Teppei Morikawa; Paul Lochhead; Yu Imamura; Aya Kuchiba; Mai Yamauchi; Katsuhiko Nosho; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2012-02-22       Impact factor: 12.531

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers.

Authors:  Kimberly D Siegmund; Paul Marjoram; Simon Tavaré; Darryl Shibata
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

View more
  81 in total

1.  Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.

Authors:  Keisuke Kosumi; Yohei Masugi; Juhong Yang; Zhi Rong Qian; Sun A Kim; Wanwan Li; Yan Shi; Annacarolina da Silva; Tsuyoshi Hamada; Li Liu; Mancang Gu; Tyler S Twombly; Yin Cao; David A Barbie; Katsuhiko Nosho; Hideo Baba; Wendy S Garrett; Jeffery A Meyerhardt; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Shuji Ogino; Reiko Nishihara
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

2.  SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.

Authors:  Tingting Li; Xiaoyun Liao; Paul Lochhead; Teppei Morikawa; Mai Yamauchi; Reiko Nishihara; Kentaro Inamura; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Aya Kuchiba; Yu Imamura; Yoshifumi Baba; Kaori Shima; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino; Zhi Rong Qian
Journal:  Ann Surg Oncol       Date:  2014-07-15       Impact factor: 5.344

Review 3.  Personalized radiotherapy: concepts, biomarkers and trial design.

Authors:  A H Ree; K R Redalen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

Review 4.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

5.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Gaya Spolverato; Aslam Ejaz; Rohan Gupta; David Cosgrove; Robert Anders; Georgios Karagkounis; Michael A Choti; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

6.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

Review 7.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

8.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Juhong Yang; Kosuke Mima; Annacarolina da Silva; Yan Shi; Kentaro Inamura; Yin Cao; Mingyang Song; Jonathan A Nowak; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott Rodig; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Gut       Date:  2016-05-05       Impact factor: 23.059

9.  Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer.

Authors:  Akiko Hanyuda; Sun A Kim; Alejandro Martinez-Fernandez; Zhi Rong Qian; Mai Yamauchi; Reiko Nishihara; Teppei Morikawa; Xiaoyun Liao; Kentaro Inamura; Kosuke Mima; Yin Cao; Xuehong Zhang; Kana Wu; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Ramesh A Shivdasani; Shuji Ogino
Journal:  Ann Surg Oncol       Date:  2015-11-17       Impact factor: 5.344

10.  Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status.

Authors:  Teppei Morikawa; Aya Kuchiba; Paul Lochhead; Reiko Nishihara; Mai Yamauchi; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Kimmie Ng; Andrew T Chan; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Res       Date:  2013-02-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.